logo
Over 44,000 pounds of Bornstein Seafoods shrimp recalled over listeria concerns

Over 44,000 pounds of Bornstein Seafoods shrimp recalled over listeria concerns

USA Today21 hours ago

Over 44,000 pounds of Bornstein Seafoods shrimp recalled over listeria concerns
Show Caption
Hide Caption
Cucumbers under recall
Cucumbers grown in Florida are part of the latest salmonella outbreak. The FDA issued a recall after the cucumbers were linked to Bedner Growers.
Fox - 13 News
A Washington-based seafood company voluntarily recalled over 44,000 pounds of ready-to-eat shrimp meat over possible contamination with Listeria monocytogenes.
The recall was the result of a "routine sampling program" conducted by the company, Bornstein Foods.
"Listeria monocytogenes was detected in an in-process shrimp sample in a food production environment," Bornstein Foods said in a June 10 notice from the Food & Drug Administration. "The company has ceased the distribution of the product as the company continues our root cause investigation as to what caused the problem."
The affected products were sold directly to distributors and retailers in three states, including California, Oregon and Washington, as well as British Columbia of Canada, according to the notice.
Bornstein Seafoods, headquartered in Bellingham, Washington, noted in its advisory that the "products may have been further distributed and sold at retailers nationwide." It's not immediately clear which, or how many distributors or retailers were sold this product. No illnesses have been reported in connection with this recall.
When contacted by USA TODAY, Bornstein Seafoods referred any questions back to the FDA's notice.
Bornstein Seafoods recall: See affected products
The easiest way for consumers to check if they have purchased and are in possession of the affected product is by verifying if the product details we share match the bag, or bags you have.
Here are some things to look for:
Product name: Bornstein Seafoods brand "Cooked & Peeled Ready-To-Eat Coldwater Shrimp Meat"
Bornstein Seafoods brand "Cooked & Peeled Ready-To-Eat Coldwater Shrimp Meat" Product information: 1 lb and 5 lb bags may be affected
Relevant Lot Codes, Item Numbers, Universal Product Codes and Master Case Label Description are listed here. The affected product has the lot code printed at the lower left corner of master case label and at the bottom on the back side of the 1 pound or 5 pound bag.
What should I do if I have the recalled shrimp meat?
Consumers who have purchased the affected product are urged to return it to the place of purchase for a full refund.
Consumers with questions may contact the company via email at Andrew@bornstein.com.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Vitamin gummies sold at ALDI and BJ's nationwide recalled
Vitamin gummies sold at ALDI and BJ's nationwide recalled

Yahoo

time8 minutes ago

  • Yahoo

Vitamin gummies sold at ALDI and BJ's nationwide recalled

(WHTM) — Several vitamin gummy supplements that were sold at ALDI and BJ's stores nationwide have been recalled. According to the U.S. Food & Drug Administration (FDA), Vita Warehouse Corp. has voluntarily recalled one lot of Welby® brand Vitamin B12 Energy Support gummy product (1000 mcg 140 gummies), Berkely Jensen® Vitamin B12 (1000 mcg 250 Gummies), and VitaGlobe™ Vitamin B12 Extra Strength (60 Gummies). Close Thanks for signing up! Watch for us in your inbox. Subscribe Now These vitamins were recalled because of the potential presence of undeclared peanuts. To date, no illnesses or allergic reactions have been reported. The FDA says this recall was initiated after ALDI conducted routine testing as part of their standard protocol to verify accuracy of allergen-related claims on product labeling. One test result indicated the potential presence of a peanut allergen. It should be noted that Vita Warehouse Corp. verified the absence of peanuts in the product, but the recall is being initiated out of an abundance of caution. According to the FDA, the recalled products were distributed at ALDI and BJ's stores nationwide and online at and The only products that are included in this recalled are: Product UPC Code Lot # Expiration Date Aldi Welby 4099100290868 248046601 10/2026 Berkley Jensen 888670132487 248046601 10/2026 VitaGlobe 850005214670 248046601 10/2026 Moving forward, consumers who are allergic to peanuts and have purchase the recalled products are urged to return them to the place of purchase for a full refund, or discard of them immediately. If you have any questions, you can contact the company at 1-855-214-0100 or email Vita Warehouse at info@ abc27 news will keep you updated as more information becomes available. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints
KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints

Yahoo

time19 minutes ago

  • Yahoo

KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints

FDA states heavy workload and limited resources prevent meeting PDUFA goal date of June 17 Agency indicates anticipated decision within four weeks CAMBRIDGE, Mass. & SALISBURY, England, June 13, 2025--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will not meet the PDUFA goal date for the New Drug Application (NDA) for sebetralstat, the Company's investigational oral on-demand treatment for hereditary angioedema (HAE). The FDA notified the Company on June 13, 2025, that the previously disclosed June 17, 2025 PDUFA goal date will not be met due to heavy workload and limited resources. The FDA indicated that it expects to deliver a decision within approximately four weeks. The FDA has not requested additional data or studies and has not raised any concerns regarding the safety, efficacy or approvability of sebetralstat. KalVista has addressed all prior information requests in a timely manner, and the Company believes the only remaining item under FDA review is the finalization of the labelling. "We are disappointed by this delay, most importantly because we know how much people living with HAE are looking forward to an oral on-demand option to treat their HAE attacks," said Ben Palleiko, CEO of KalVista. "At the same time, we remain confident in the near-term approval of sebetralstat. We are continuing to work closely with the FDA to support the completion of their review. Our commitment to bringing this important therapy to people living with HAE remains unwavering." About Sebetralstat Sebetralstat is an investigational, novel oral plasma kallikrein inhibitor for the treatment of hereditary angioedema (HAE). We have filed multiple regulatory applications seeking approval of sebetralstat as the first oral, on-demand treatment for HAE in individuals aged 12 and older and are investigating its use in children aged 2 to 11. If approved, sebetralstat has the potential to become the foundational therapy for HAE management worldwide. About Hereditary Angioedema Hereditary angioedema (HAE) is a rare genetic disease resulting in deficiency or dysfunction in the C1 esterase inhibitor (C1INH) protein and subsequent uncontrolled activation of the kallikrein-kinin system. People living with HAE experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected. All currently approved on-demand treatment options require either intravenous or subcutaneous administration. About KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. Our lead investigational product is sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE). Sebetralstat is under regulatory review by the U.S. FDA. In addition, we have completed Marketing Authorization Applications for sebetralstat to the European Medicines Agency and multiple other global regulatory authorities. For more information about KalVista, please visit or follow us on social media at @KalVista and LinkedIn. Forward-Looking Statements This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our KONFIDENT-S and KONFIDENT-KID trials, and to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2024, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. View source version on Contacts Ryan BakerHead, Investor Relations(617) Molly CameronDirector, Corporate Communications(978) Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten

NVO Stock up on Plans to Advance Obesity Candidate Amycretin
NVO Stock up on Plans to Advance Obesity Candidate Amycretin

Yahoo

time21 minutes ago

  • Yahoo

NVO Stock up on Plans to Advance Obesity Candidate Amycretin

Novo Nordisk NVO announced plans to advance amycretin, for weight management, into late-stage development. Amycretin is being developed for subcutaneous and oral administration. Shares of this Denmark-based company gained 2.95% on June 12, following the announcement. Oral amycretin is a novel, unimolecular co-agonist of both GLP-1 and amylin receptors being developed by Novo Nordisk to provide an efficacious and convenient treatment for obesity and type 2 diabetes in adults. NVO decided to advance the candidate into phase III based on feedback received from regulatory authorities following end-of-phase II interactions for subcutaneous and oral amycretin in weight management. A phase I study evaluated the single-ascending dose and multiple-ascending doses for oral amycretin, up to 2 times 50 mg, in people with overweight or obesity, with a total treatment duration of up to 12 weeks. A phase Ib/IIa study investigated the safety, tolerability, pharmacokinetics, and proof-of-concept of once-weekly subcutaneous amycretin in people with overweight or obesity. The trial was a combined single ascending dose, multiple ascending dose and dose-response trial investigating three different maintenance doses with a total treatment duration of up to 36 weeks. The phase III program on amycretin is planned to be initiated during the first quarter of 2026. Buoyed by the stupendous success of its blockbuster semaglutide products, Wegovy (obesity) and Ozempic (diabetes), NVO is now developing several next-generation candidates in its pipeline, especially targeting the lucrative U.S. market. CagriSema, a fixed-dose combination of a long-acting amylin analogue and Wegovy, is the most advanced candidate in Novo Nordisk's obesity pipeline. Novo Nordisk will present full results from the phase III REDEFINE 1 and 2 studies on CagriSema shortly. Management stated that the REDEFINE 1 and 2 studies will provide insights into the transformational potential of CagriSema. The FDA accepted Novo Nordisk's regulatory application, seeking the approval of oral semaglutide 25 mg for obesity, for review. A final decision from the regulatory body is expected around the turn of the year. Year to date, Novo Nordisk's shares have lost 4.7% against the industry's growth of 2.9%. Image Source: Zacks Investment Research The stock price was under pressure at the start of the year due to recent market challenges. Stiff competition in the obesity market from its arch-rival, Eli Lilly LLY, along with pipeline and regulatory setbacks, weighed on the share price. We note that NVO's semaglutide drugs have only been off the FDA's supply shortage list since February 2025. Eli Lilly markets its tirzepatide medicines as Mounjaro for T2D and Zepbound for obesity. Like NVO, LLY is also evaluating several next-generation weight loss candidates. LLY, too, has achieved stupendous success for its obesity drugs. Nonetheless, NVO stock has witnessed some recovery this week. Novo Nordisk gained 5% on June 10, following a report that activist hedge fund Parvus Asset Management is building a stake in the company. Per the Financial Times, this London-based hedge fund is raising its stake in NVO to influence the appointment of the company's new chief executive officer (CEO). Last month, shares of the company dipped after it announced that CEO Lars Fruergaard Jørgensen would step down from his position following a mutual agreement with the company's board. Novo Nordisk currently carries a Zacks Rank #3 (Hold). A couple of better-ranked large-cap pharma stocks are Novartis NVS and Bayer BAYRY, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The Zacks Consensus Estimate for Novartis' 2025 earnings per share (EPS) has risen from $8.46 to $8.74 over the past 60 days. EPS estimates for 2026 have jumped 35 cents to $9.02 during this timeframe. The stock has risen 27% so far this year. BAYRY's 2025 EPS estimate has increased from $1.19 to $1.25 for 2025 over the past 60 days, while that for 2026 has gone up from $1.28 to $1.31 over the same timeframe. Year to date, shares of Bayer have surged 65.1%. BAYRY's earnings beat estimates in one of the trailing four quarters, matched twice and missed on the remaining occasion, the average negative surprise being 13.91%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store